Search Results - Burdeska, A.

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
    Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension

    Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension by Bianchi, G., Czerwinski, E., Kenwright, A., Burdeska, A., Recker, R. R., Felsenberg, D.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women

    Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women by Stakkestad, J A, Benevolenskaya, L I, Stepan, J J, Skag, A, Nordby, A, Oefjord, E, Burdeska, A, Jonkanski, I, Mahoney, P

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Oral Daily Ibandronate Prevents Bone Loss in Early Postmenopausal Women Without Osteoporosis

    Oral Daily Ibandronate Prevents Bone Loss in Early Postmenopausal Women Without Osteoporosis by Mcclung, Michael R, Wasnich, Richard D, Recker, Robert, Cauley, Jane A, Chesnut, Charles H, Ensrud, Kristine E, Burdeska, Alexander, Mills, Tracy

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Oral weekly ibandronate prevents bone loss in postmenopausal women

    Oral weekly ibandronate prevents bone loss in postmenopausal women by Tankó, L. B., Felsenberg, D, Czerwiński, E, Burdeska, A, Jonkanski, I, Hughes, C, Christiansen, C

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Oral Daily Ibandronate Prevents Bone Loss in Early Postmenopausal Women Without Osteoporosis

    Oral Daily Ibandronate Prevents Bone Loss in Early Postmenopausal Women Without Osteoporosis by McClung, M R, Wasnich, R D, Recker, R, Cauley, JA, Chesnut, CH III, Ensrud, KE, Burdeska, A, Mills, T

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Clinical consequences of development of resistance to third generation cephalosporins

    Clinical consequences of development of resistance to third generation cephalosporins by Follath, F., Costa, E., Thommen, A., Frei, R., Burdeska, A., Meyer, J.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  7. 7
    Previous Phase II Studies In Severe Sepsis/Septic Shock Have Been Too Small To Constitute Adequate Basis For Phase III: 35

    Previous Phase II Studies In Severe Sepsis/Septic Shock Have Been Too Small To Constitute Adequate Basis For Phase III: 35 by Leighton, A., Abraham, E., Zwingelstein, C., Burdeska, A., Staeger, S., Passe, S., Van der Auwera, Ph

    Published in Shock (Augusta, Ga.)
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Previous Phase II Studies In Severe Sepsis/Septic Shock Have Been Too Small To Constitute Adequate Basis For Phase III: 35

    Previous Phase II Studies In Severe Sepsis/Septic Shock Have Been Too Small To Constitute Adequate Basis For Phase III: 35 by Leighton, A., Abraham, E., Zwingelstein, C., Burdeska, A., Staeger, S., Passe, S., Van der Auwera, Ph

    Published in Shock (Augusta, Ga.)
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Identical genes for trimethoprim-resistant dihydrofolate reductase from Staphylococcus aureus in Australia and Central Europe

    Identical genes for trimethoprim-resistant dihydrofolate reductase from Staphylococcus aureus in Australia and Central Europe by Burdeska, Alexander, Ott, Michael, Bannwarth, Willi, Then, Rudolf L.

    Published in FEBS letters
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  10. 10
    Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate: mobile 2-year analysis

    Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate: mobile 2-year analysis by Czerwinski, E., Nuti, R., Greenwald, M., Burdeska, A., Leigh, C., Reginster, Jean-Yves

    Get full text
    Web Resource
    Save to List
    Saved in:
  11. 11
    Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial

    Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial by Muntoni, Francesco, Bertini, Enrico, Comi, Giacomo, Kirschner, Janbernd, Lusakowska, Anna, Mercuri, Eugenio, Scoto, Mariacristina, van der Pol, W Ludo, Vuillerot, Carole, Burdeska, Alexander, El-Khairi, Muna, Fontoura, Paulo, Ives, Jane, Gorni, Ksenija, Reid, Carol, Fuerst-Recktenwald, Sabine

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: